In recognition of Thyroid Awareness Month 2025, our Guidelines Rundown Series continues with a new article focusing on the most popular thyroid guidelines of 2024. According to the National Institutes of Health (NIH), nearly 5 out of 100 Americans aged 12 years and older have hypothyroidism, with most cases being mild or showing few symptoms. […]
Read More
Welcome to the latest edition of our Guideline Spotlight, where we will explore the valuable insights and key takeaways from the most recent guideline releases. Today, our focus is on the American Diabetes Association’s (ADA) latest edition of their Standards of Care in Diabetes, which was released on December 9, 2024. This edition consolidates all […]
Read More
Diabetic retinopathy, the most prevalent microvascular complication of both type 1 and type 2 diabetes, stands as a primary contributor to new cases of vision impairment among individuals aged 20 to 74 in the United States. This condition serves as the ocular manifestation of end-organ damage in diabetes mellitus. Factors that heighten the risk of […]
Read More
The 2024 American Thyroid Association (ATA) Annual Meeting took place from October 30 to November 3 in Chicago, IL. This event is globally recognized as the premier gathering for individuals interested in thyroid diseases and disorders. Attendees had the opportunity to engage in peer-to-peer learning and collaboration through a variety of activities including lectures, interactive […]
Read MoreWelcome to the latest edition of our Guidelines+ Monographs Series. In this installment, we will delve into the medication aflibercept, marketed under the brand name Eylea by Regeneron Pharmaceuticals, Inc. Eylea a is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema […]
Read More
Affecting more than one-third of adults in the US, obesity remains a pressing health challenge for both providers and patients, conferring significant risk for comorbidities such as type 2 diabetes, obstructive sleep apnea, and cardiovascular disease. While lifestyle modifications and medical therapies, including anti-obesity medications (AOM), can be effective for some, they often fall short […]
Read MoreIn this edition of our Guidelines Monographs Series, we will be taking a look at AstraZeneca’s medication dapagliflozin, brand name Farxiga. Initially approved in 2014, Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, provided to individuals with diabetes, heart disease, or kidney disease to improve their outcomes. This Guidelines+ Monograph will take a deeper dive […]
Read More
High cholesterol, also known as hyperlipidemia, affects millions of individuals in the United States (US). This condition can lead to serious health issues, such as an increased risk of heart disease and stroke. Globally, approximately one-third of cases of ischaemic heart disease are linked to high cholesterol levels. Elevated total cholesterol is a significant contributor […]
Read More
Thyroid eye disease (TED), also known as Graves’ orbitopathy, is a complex immune-mediated disorder characterized by the aberrant proliferation of orbital fibroblasts, adipogenesis, glycosaminoglycan and mucin deposition. This connective tissue remodeling results in edematous, fibrotic adipose tissue and inflammation within the orbit and underlies the consequential classic presentation of proptosis, where the eyes appear pushed […]
Read More